FDA Clears Calypso(R) Medical’s GPS For The Body(R) For Prostatectomy Patients

Calypso(R) Medical announced that the U.S. Food and Drug Administration (FDA) cleared a new indication for the use of implantable Beacon® electromagnetic transponders with the Calypso System in external beam radiation therapy. Known as GPS for the Body®, the Calypso System utilizes transponders to setup and continuously track the position of targeted tissue during radiation treatment.

More: continued here

Filed under: Radiology on May 22nd, 2008